{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:00:04Z","timestamp":1794315604433,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this study, we aimed to design a novel oral insulin delivery system, named \u201coil-soluble\u201d reversed lipid nanoparticles (ORLN), in which a hydrophilic insulin molecule is encapsulated by a phospholipid (PC) shell and dissolved in oil to prevent the enzymatic degradation of insulin. ORLN was characterized by transmission electron microscopy and dynamic light scattering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro enzymatic stability studies showed higher concentrations of insulin in cells incubated with ORLN-encapsulated insulin than in those incubated with free insulin solution in artificial intestinal fluid (pH 6.5). The protective effect of ORLN was attributed to its special release behavior and the formulation of the PC shell and oil barrier. Furthermore, an in vivo oral efficacy study confirmed that blood glucose levels were markedly decreased after ORLN administration in both healthy and diabetic mice. In vivo pharmacokinetic results showed that the bioavailability of ORLN-conjugated insulin was approximately 28.7% relative to that of the group subcutaneously administered with an aqueous solution of insulin, indicating enhanced oral absorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, the ORLN system developed here shows promise as a nanocarrier for improving the oral absorption of insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-020-00657-8","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:26:01Z","timestamp":1594981561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["\u201cOil-soluble\u201d reversed lipid nanoparticles for oral insulin delivery"],"prefix":"10.1186","volume":"18","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-5175","authenticated-orcid":false,"given":"Dongqin","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/08982100009031106","volume":"10","author":"CJ Kirby","year":"2000","unstructured":"Kirby CJ. Oil-based formulations for oral delivery of therapeutic peptides. J Liposome Res. 2000;10:391\u2013407.","journal-title":"J Liposome Res"},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1073\/pnas.1722338115","volume":"115","author":"A Banerjee","year":"2018","unstructured":"Banerjee A, Ibsen K, Brown T, Chen R, Agatemor C, Mitragotri S. Ionic liquids for oral insulin delivery. Proc Natl Acad Sci USA. 2018;115:7296\u2013301.","journal-title":"Proc Natl Acad Sci USA."},{"key":"657_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","volume":"106","author":"TAS Aguirre","year":"2016","unstructured":"Aguirre TAS, Teijeiro-Osorio D, Rosa M, Coulter IS, Alonso MJ, Brayden DJ. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016;106:223\u201341.","journal-title":"Adv Drug Deliv Rev"},{"key":"657_CR4","first-page":"101","volume-title":"Peptides: chemistry and biology","author":"S Norbert","year":"2002","unstructured":"Norbert S, Hans-Dieter J. Peptides: chemistry and biology. New york: Wiley; 2002. p. 101."},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/1932296817691303","volume":"11","author":"E Arbit","year":"2017","unstructured":"Arbit E, Kidron M. Oral insulin delivery in a physiologic context: review. J Diabetes Sci Technol. 2017;11:825\u201332.","journal-title":"J Diabetes Sci Technol"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/193229681300700228","volume":"7","author":"P Fonte","year":"2013","unstructured":"Fonte P, Ara\u00fajo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7:520\u201331.","journal-title":"J Diabetes Sci Technol"},{"key":"657_CR7","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2337\/dc09-1807","volume":"33","author":"C Kapitza","year":"2010","unstructured":"Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010;33:1288\u201390.","journal-title":"Diabetes Care"},{"key":"657_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","volume":"447","author":"J Renukuntla","year":"2013","unstructured":"Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013;447:75\u201393.","journal-title":"Int J Pharm"},{"key":"657_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijpharm.2012.03.056","volume":"440","author":"MR Rekha","year":"2013","unstructured":"Rekha MR, Sharma CP. Oral delivery of therapeutic protein\/peptide for diabetes\u2013future perspectives. Int J Pharm. 2013;440:48\u201362.","journal-title":"Int J Pharm"},{"key":"657_CR10","unstructured":"The search results for oral insulin. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=oral+insulin&cntry=&state=&city=&dist=."},{"key":"657_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1932296814529988","volume":"8","author":"E Zijlstra","year":"2014","unstructured":"Zijlstra E, Heinemann L, Plum-M\u00f6rschel L. Oral insulin reloaded: a structured approach. J Diabetes Sci Technol. 2014;8:458\u201365.","journal-title":"J Diabetes Sci Technol"},{"key":"657_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/10717544.2017.1386730","volume":"24","author":"T Wang","year":"2017","unstructured":"Wang T, Shen L, Zhang Z, Li H, Huang R, Zhang Y, et al. A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption. Drug Deliv. 2017;24:1565\u201373.","journal-title":"Drug Deliv"},{"key":"657_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/10717544.2017.1330373","volume":"24","author":"L Shen","year":"2017","unstructured":"Shen L, Zhang Z, Wang T, Yang X, Huang R, Quan D. Reversed lipid-based nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection. Drug Deliv. 2017;24:857\u201366.","journal-title":"Drug Deliv"},{"key":"657_CR14","doi-asserted-by":"publisher","first-page":"e57136","DOI":"10.1371\/journal.pone.0057136","volume":"8","author":"V Gupta","year":"2013","unstructured":"Gupta V, Doshi N, Mitragotri S. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLoS ONE. 2013;8:e57136.","journal-title":"PLoS ONE"},{"key":"657_CR15","first-page":"5031","volume":"14","author":"Li Tian","year":"2014","unstructured":"Tian Li, Ya-lou Zhang, et al. Study of type 1 diabetes model induced by streptozotocin in the C57 mouse. Progress Modern Biomed. 2014;14:5031\u20133.","journal-title":"Progress Modern Biomed"},{"key":"657_CR16","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1016\/j.biomaterials.2011.08.087","volume":"32","author":"MC Chen","year":"2011","unstructured":"Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32:9826\u201338.","journal-title":"Biomaterials"},{"key":"657_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jconrel.2006.10.023","volume":"117","author":"C Damg\u00e9","year":"2007","unstructured":"Damg\u00e9 C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release. 2007;117:163\u201370.","journal-title":"J Control Release"},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1016\/j.biomaterials.2009.06.055","volume":"30","author":"L Yin","year":"2009","unstructured":"Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials. 2009;30:5691\u2013700.","journal-title":"Biomaterials"},{"key":"657_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jconrel.2012.11.005","volume":"165","author":"K Chaturvedi","year":"2013","unstructured":"Chaturvedi K, Ganguly K, Nadagouda MN, Aminabhavi TM. Polymeric hydrogels for oral insulin delivery. J Control Release. 2013;165:129\u201338.","journal-title":"J Control Release"},{"key":"657_CR20","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.biomaterials.2011.12.038","volume":"33","author":"FY Su","year":"2012","unstructured":"Su FY, Lin KJ, Sonaje K, Wey SP, Yen TC, Ho YC, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials. 2012;33:2801\u201311.","journal-title":"Biomaterials"},{"key":"657_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejps.2010.12.007","volume":"42","author":"A Makhlof","year":"2011","unstructured":"Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci. 2011;42:445\u201351.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"657_CR22","first-page":"573","volume":"33","author":"Y Jin","year":"2012","unstructured":"Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials. 2012;33(1):573\u201382.","journal-title":"Biomaterials"},{"key":"657_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/1567201053586001","volume":"2","author":"D Malkov","year":"2005","unstructured":"Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen(\u00ae) technology: mechanistic studies. Curr Drug Deliv. 2005;2:191\u20137.","journal-title":"Curr Drug Deliv"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-020-00657-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T19:44:42Z","timestamp":1626464682000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-020-00657-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s12951-020-00657-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25661\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25661\/v2","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments of this study were carried out at Experimental Animal Center, Beijing Institute of Pharmacology and Toxicology, and were approved by Experimental Animal Ethics Committee of Beijing Institute of Pharmacology and Toxicology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}